Loibl S, Poortmans P, Morrow M, Denkert C, Curigliano G. Breast cancer. The Lancet. 2021;397:1750–69.
Zhang L, Fang C, Xu X, Li A, Cai Q, Long X. Androgen receptor, EGFR, and BRCA1 as biomarkers in triple-negative breast cancer: a meta-analysis. Biomed Res Int. 2015;2015:1–12.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011;121:2750–67.
Article CAS PubMed PubMed Central Google Scholar
Khan MA, Jain VK, Rizwanullah Md, Ahmad J, Jain K. PI3K/AKT/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges. Drug Discovery Today. 2019;24:2181–91.
Article CAS PubMed Google Scholar
López-Knowles E, O’Toole SA, McNeil CM, Millar EKA, Qiu MR, Crea P, et al. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality: PI3K pathway activation and breast cancer outcome. Int J Cancer. 2010;126:1121–31.
Najminejad Z, Dehghani F, Mirzaei Y, Mer AH, Saghi SA, Abdolvahab MH, et al. Clinical perspective: antibody-drug conjugates for the treatment of HER2-positive breast cancer. Mol Ther. 2023;31:1874–903.
Article CAS PubMed Google Scholar
Ye F, Dewanjee S, Li Y, Jha NK, Chen Z-S, Kumar A, et al. Advancements in clinical aspects of targeted therapy and immunotherapy in breast cancer. Mol Cancer. 2023;22:105.
Article CAS PubMed PubMed Central Google Scholar
Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002;296:1655–7.
Article CAS PubMed Google Scholar
LoRusso PM. Inhibition of the PI3K/AKT/mTOR pathway in solid tumors. JCO. 2016;34:3803–15.
Csolle MP, Ooms LM, Papa A, Mitchell CA. PTEN and other PtdIns(3,4,5)P3 lipid phosphatases in breast cancer. IJMS. 2020;21:9189.
Article CAS PubMed PubMed Central Google Scholar
Eramo MJ, Mitchell CA. Regulation of PtdIns(3,4,5)P3/Akt signalling by inositol polyphosphate 5-phosphatases. Biochem Soc Trans. 2016;44:240–52.
Article CAS PubMed Google Scholar
Pascual J, Turner NC. Targeting the PI3-kinase pathway in triple-negative breast cancer. Ann Oncol. 2019;30:1051–60.
Article CAS PubMed Google Scholar
Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell. 2017;170:605–35.
Article CAS PubMed PubMed Central Google Scholar
Miricescu D, Totan A, Stanescu-Spinu I-I, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2021;22:173.
The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61–70.
Article PubMed Central Google Scholar
Hu H, Zhu J, Zhong Y, Geng R, Ji Y, Guan Q, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Ann Transl Med. 2021;9:410–410.
Article CAS PubMed PubMed Central Google Scholar
Pierobon M, Ramos C, Wong S, Hodge KA, Aldrich J, Byron S, et al. Enrichment of PI3K-AKT–mTOR pathway activation in hepatic metastases from breast cancer. Clin Cancer Res. 2017;23:4919–28.
Article CAS PubMed PubMed Central Google Scholar
Revathidevi S, Munirajan AK. Akt in cancer: mediator and more. Semin Cancer Biol. 2019;59:80–91.
Article CAS PubMed Google Scholar
Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature. 2007;448:439–44.
Article CAS PubMed Google Scholar
Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Targeting Akt3 signaling in triple-negative breast cancer. Can Res. 2014;74:964–73.
Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease. Cell. 2017;168:960–76.
Article CAS PubMed PubMed Central Google Scholar
Presti D, Quaquarini E. The PI3K/AKT/mTOR and CDK4/6 pathways in endocrine resistant HR+/HER2−metastatic breast cancer: biological mechanisms and new treatments. Cancers. 2019;11:1242.
Article CAS PubMed PubMed Central Google Scholar
Hsu PP, Kang SA, Rameseder J, Zhang Y, Ottina KA, Lim D, et al. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science. 2011;332:1317–22.
Article CAS PubMed PubMed Central Google Scholar
Ben-Sahra I, Hoxhaj G, Ricoult SJH, Asara JM, Manning BD. mTORC1 induces purine synthesis through control of the mitochondrial tetrahydrofolate cycle. Science. 2016;351:728–33.
Article CAS PubMed PubMed Central Google Scholar
Huang J, Dibble CC, Matsuzaki M, Manning BD. The TSC1-TSC2 complex is required for proper activation of mTOR complex 2. Mol Cell Biol. 2008;28:4104–15.
Article CAS PubMed PubMed Central Google Scholar
Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA, et al. The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell. 2004;6:91–9.
Article CAS PubMed Google Scholar
Bhola NE, Jansen VM, Koch JP, Li H, Formisano L, Williams JA, et al. Correction: treatment of triple-negative breast cancer with TORC1/2 inhibitors sustains a drug-resistant and notch-dependent cancer stem cell population. Can Res. 2019;79:875–875.
Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998;95:29–39.
Article CAS PubMed Google Scholar
Chai C, Wu HH, Abuetabh Y, Sergi C, Leng R. Regulation of the tumor suppressor PTEN in triple-negative breast cancer. Cancer Lett. 2022;527:41–8.
Article CAS PubMed Google Scholar
Dillon L, Miller T. Therapeutic targeting of cancers with loss of PTEN function. CDT. 2014;15:65–79.
Wang C, Bian Z, Wei D, Zhang J. miR-29b regulates migration of human breast cancer cells. Mol Cell Biochem. 2011;352:197–207.
Article CAS PubMed Google Scholar
Shi W, Gerster K, Alajez NM, Tsang J, Waldron L, Pintilie M, et al. MicroRNA-301 mediates proliferation and invasion i
Comments (0)